The FDA approved Eli Lilly and Boehringer Ingelheim’s Glyxambi (empagliflozin/linagliptin) as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes, the companies reported Monday. The program is made possible through $1.5 million in funding from Boehringer Ingelheim and is directed, managed and overseen by the Association. and Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Jardiance® works by blocking the reabsorption of glucose (blood sugar) by the kidney, leading to urinary glucose excretion, and lowering blood glucose levels in people with type 2 diabetes. The global survey will provide a snapshot of the current perceptions of both physicians and people living with type 2 diabetes about these important early conversations and will highlight challenges and potential areas for improvement. Patients with diabetes often receive treatments across multiple medical specialties for a multitude of related conditions. The results showed that treatment with empagliflozin (10mg and 25mg) when added to metformin, with or without other standard blood glucose-lowering drugs, led to statistically significant reductions in blood glucose, body weight and a clinically relevant reduction in blood pressure.
Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine. Headquartered in Ingelheim, Germany, it operates globally with 140 affiliates and more than 46,000 employees. The primary endpoint was defined as time to first occurrence of CV death, non-fatal heart attack or non-fatal stroke. Initial combination treatment with empagliflozin and metformin was part of an investigational trial. have chronic heart failure. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where Boehringer Ingelheim and Eli Lilly and Company do business. About Eli Lilly and Company Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organisations.
The American College of Cardiology is a 49,000-member medical society that is the professional home for the entire cardiovascular care team. Additional information about Lilly is available at www.lilly.com. This does not alter the authors’ adherence to PLOS ONE policies on sharing data and materials. About Boehringer Ingelheim The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. There is no guarantee that future study results and patient experience will be consistent with study findings to date or that linagliptin will prove to be commercially successful. For further discussion of these and other risks and uncertainties, please see Lilly’s latest Forms 10-Q and 10-K filed with the U.S. Securities and Exchange Commission.
Ask your doctor or pharmacist for a list of these medicines if you are not sure if your medicine is one that is listed above.